Physician profile
Pavan V Dontineni
NPI 1790944866
$31,916.77
in general payments reported to CMS, 2019-2025
19 companies · $22.85 in 2025
The $22.85 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $28.31 · 2021: $494 · 2022: $404 · 2023: $27K · 2024: $3,883 · 2025: $22.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,050.00 |
| Food and Beverage | $1,598.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,251.32 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $387.32 | 2019-2024 | Abilify Maintena, Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $273.31 | 2019-2022 | |
| Axsome Therapeutics, INC. | $213.57 | 2023 | Auvelity |
| Alkermes, INC. | $143.03 | 2019-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.13 | 2020-2024 | Caplyta |
| Indivior INC. | $104.68 | 2023-2024 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $96.89 | 2019-2024 | Invega Sustenna, Invega Trinza, Invega |
| Avanir Pharmaceuticals, INC. | $87.73 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.14 | 2019-2023 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $59.56 | 2019 | |
| Lundbeck LLC | $32.72 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $18.31 | 2024 | Ingrezza |
| Orexo US, INC. | $16.64 | 2023 | Zubsolv |
| Validus Pharmaceuticals LLC | $15.65 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $14.82 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.22 | 2024 | Cobenfy |
| Allergan, INC. | $11.79 | 2019 | |
| Corium, LLC | $8.94 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Dontineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.